Veterinarians and producers are using science-based tools like FARAD, PBPK modeling, and targeted treatment protocols to prevent drug residues from entering the food supply. These approaches provide ...

Certara’s updated fair value estimate has shifted from US$8.99 to US$8.71, a small reset that still sits in the same broad price target zone as recent Street moves toward roughly US$8 to US$10. Those ...

Simulations Plus is a global leader in model-informed and AI-accelerated drug development. We create value for our clients by accelerating the discovery, development, and commercialization of ...

Earnings call Simulations Plus delivered Q2 revenue of $24.3M, up 8% YoY, exceeding top-line guidance with strong software and services growth. Adjusted EBITDA margin reached 36%, and management ...

Suraxavir marboxil (GP681) is an orally available prodrug that is converted in vivo to the active metabolite GP1707D07, a PA-targeting antiviral against influenza. Because GP1707D07 is primarily ...

Objectives: Pharmaceutical cocrystals are typically formed by combining an active pharmaceutical ingredient with a coformer to enhance drug solubility, stability and dissolution, thereby improving ...

RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc., a global leader in biosimulation, today announced that the European Medicines Agency (EMA) has formally qualified the Simcyp® Simulator ...

Forbes contributors publish independent expert analyses and insights. I write about the economics of AI. The AI boom has been defined by unprecedented innovation across nearly every sector. From ...

PRINCETON, N.J.--(BUSINESS WIRE)--Certara, Inc., the global leader in biosimulation, today announced the release of version 20 of its Simcyp™ Physiologically-based Pharmacokinetic (PBPK) Simulator ...

(RTTNews) - Certara, Inc. (CERT),on Tuesday announced the release of Simcyp Simulator Version 24, enhancing physiologically-based pharmacokinetic or PBPK modeling to support drug development and ...